Food and Drug Administration (FDA)

By Kate Greenwood
In Monday Morning Recap
Jun 2nd, 2014
0 Comments
Here’s this week’s Monday Morning Recap, the post where we call out the drug and device law and policy developments that caught our eye and made us think over the previous week.  You can see all of our previous Monday Morning Recap posts here. Credit for the format goes to Seton Hall Law alum Jordan […]...
By Kate Greenwood
In Monday Morning Recap
Apr 28th, 2014
2 Comments
What follows is a weekly feature here at Health Reform Watch.  Each Monday, we provide a recap of the drug and device law and policy developments over the previous week that caught our eye and made us think.  Credit for the format goes to Seton Hall Law alum Jordan T. Cohen, who used it to […]...
By Kate Greenwood
In Monday Morning Recap
Feb 24th, 2014
0 Comments
What follows is a weekly feature here at Health Reform Watch.  Each Monday, we provide a recap of the drug and device law and policy developments over the previous week that caught our eye and made us think.  Credit for the format goes to Seton Hall Law alum Jordan T. Cohen, who used it to […]...
By Kate Greenwood
In Monday Morning Recap
Feb 3rd, 2014
0 Comments
What follows is a weekly feature here at Health Reform Watch.  Each Monday, we provide a recap of the drug and device law and policy developments over the previous week that caught our eye and made us think.  Credit for the format goes to Seton Hall Law alum Jordan T. Cohen, who used it to […]...
By Jordan Paradise
In Drugs & Devices
Jan 29th, 2014
0 Comments
Debate continues regarding the Food and Drug Administration (FDA) proposed rule that would allow generic drug manufacturers to independently make changes to a drug label on the basis of newly acquired safety information.  The proposed rule trails a trilogy of Supreme Court decisions tackling questions of federal preemption in the pharmaceutical realm: Wyeth v. Levine [...